<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114493">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02150967</url>
  </required_header>
  <id_info>
    <org_study_id>CBGJ398X2204</org_study_id>
    <secondary_id>2013-005085-19</secondary_id>
    <nct_id>NCT02150967</nct_id>
  </id_info>
  <brief_title>A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma</brief_title>
  <official_title>A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Thailand: Food and Drug Administration</authority>
    <authority>France: National Agency for the Safety of Medicines and Health Products (MSNA)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Singapore: Clinical Trials &amp; Epidemiology Research Unit (CTERU)</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open label, single arm phase II study evaluating BGJ398 anti-tumor
      activity in advanced or metastatic cholangiocarcinoma patients with FGFR genetic
      alterations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with histologically or cytologically confirmed advanced or metastatic
      cholangiocarcinoma with FGFR2 gene fusion/ translocation or other FGFR genetic alteration
      who have evidence of radiologic progression following a cisplatin-and gemcitabine-containing
      regimen for advanced disease or a gemcitabine-containing regimen for those who are
      considered intolerant to cisplatin will be enrolled.  Approximately 55 adult patients over
      age 18, both male and female will be enrolled. Of these 55 patients, 40 patients will have
      cholangiocarcinoma with identified FGFR2 gene fusions and up to 15 patients may have other
      FGFR genetic alterations. All patients will receive oral BGJ398, once daily, on a three
      weeks on (21 days), one week off (7 days) schedule. One treatment cycle will consists of 28
      days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall response rate (ORR) is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR), as per RECIST version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Survival (OS) is defined as the time from the date of start of treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression free survival (PFS) is defined as the date of the start of treatment to the date of the event defined as the first documented progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The best overall response is the best response recorded from the start of the treatment until disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease control rate (DCR) is the proportion of patients with a best overall response of CR or PR or SD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs) as a measure of safety and tolerability</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To characterize the safety and tolerability of single agent BGJ398 by the type, frequency and severity of AEs &amp; SAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selected trough and 2-hr Plasma concentration profile</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine selected trough and 2-hr plasma concentrations of BGJ398</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Advanced Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>BGJ398</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To estimate anti-tumor activity of BGJ398</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGJ398</intervention_name>
    <description>Capsule for oral use</description>
    <arm_group_label>BGJ398</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inlcusion criteria:

          -  Patients with histologically or cytologically confirmed cholangiocarcinoma at the
             time of diagnosis.

          -  Patients must have received at least one prior regimen containing gemcitabine with or
             without cisplatin for advanced or metastatic disease. Patient must have evidence of
             progressive disease following prior regimen.

        Main exclusion criteria:

          -  Prior or current treatment with an FGFR inhibitor

          -  insufficient organ function

               -  ANC &lt; 1,000/mm3 [1.0 x 109/L]

               -  Platelets &lt; 75,000/mm3 [75 x 109/L]

               -  Hemoglobin &lt; 109.0 g/dL

               -  Total bilirubin &gt; 1.5x ULN

               -  AST/SGOT and ALT/SGPT &gt; 2.5x ULN (AST and ALT &gt; 5x ULN in the presence of  liver
                  metastases)

               -  Serum creatinine &gt; ULN and/or calculated or measured creatinine clearance &lt; 75%
                  LLN

               -  Inorganic phosphorus outside of normal limits

               -  Total and ionized serum calcium outside of normal limits
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona Dept of Oncology</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurie Mihalik</last_name>
      <phone>480-342-3256</phone>
      <email>Mihalik.laurie@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mitesh J. Borad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles UCLA SC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Maravola</last_name>
      <phone>310-582-6324</phone>
      <email>CMaravola@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Saeed Sadeghi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC/Kenneth Norris Comprehensive Cancer Center Onc Dept</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeno Ashai</last_name>
      <phone>323-865-3957</phone>
      <email>Zeno.Ashai@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony El-Khoueiry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Onc Dept</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jane Regalado</last_name>
      <phone>312-695-4168</phone>
      <email>jregalad@nmh.org</email>
    </contact>
    <investigator>
      <last_name>Al Benson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Dept. of Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashley O'Meara</last_name>
      <phone>617-724-9533</phone>
      <email>alomeara@partners.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute Onc. Department</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Budde</last_name>
      <phone>313-576-9385</phone>
      <email>budded@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Philip A. Philip</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Sloan Onc Dept.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerry O'Neill</last_name>
      <phone>646-888-4330</phone>
      <email>Oneillg@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Ghassan K. Abou-Alfa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine Onc Dept.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivy S. Cohen</last_name>
      <phone>212-824-7319</phone>
      <email>Ivy.cohen@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Celina Ang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept of Onc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sona Hardikar</last_name>
      <phone>614-293-9863</phone>
      <email>sona.hardikar@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Tanios Bekaii-Saab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center Onc. Dept,</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samia Aziz</last_name>
      <phone>713-563-7757</phone>
      <email>saziz@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Milind Javle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>France</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>May 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cholangiocarcinoma,</keyword>
  <keyword>FGFR2 gene fusion,</keyword>
  <keyword>FGFR genetic alteration</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
